SCHEMBL7175126

SCHEMBL7175126

Cc1nc(-c2ccc(-c3ccc(C(=O)N4CCCc5cc6c(cc54)C(CCN(C)C)CO6)cc3)c(C)c2)no1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1D P28221 15/20 0.59
HTR1B P28222 13/20 0.59
HTR2A P28223 10/20 0.59
MEN1 O00255 5/20 0.55
MAPT P10636 5/20 0.55
KMT2A Q03164 5/20 0.55
TDP1 Q9NUW8 5/20 0.55
MAPK1 P28482 4/20 0.55
SLC6A4 P31645 4/20 0.55
TP53 P04637 3/20 0.55
CYP3A4 P08684 3/20 0.55
CYP2D6 P10635 3/20 0.55
HTR2C P28335 3/20 0.55
CYP1A2 P05177 2/20 0.55
CHRM2 P08172 2/20 0.55
ADRA2A P08913 2/20 0.55
CHRM1 P11229 2/20 0.55
ADRA2B P18089 2/20 0.55
FPR1 P21462 2/20 0.55
SLC6A2 P23975 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL30227183 0.98 HTR1D (0.57) HTR1DHTR1BHTR2AMEN1MAPT
Oxalic Acid SCHEMBL6925627 0.98 HTR1D (0.57) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8148935 0.96 HTR1D (0.65) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8154130 0.91 HTR1D (0.59) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8147188 0.82 HTR1D (0.66) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL5432776 0.79 HTR1D (0.91) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8816217 0.78 HTR1D (0.62) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8389415 0.78 HTR1D (0.72) HTR1DHTR1BHTR2AMEN1MAPT
SCHEMBL8154054 0.78 HTR1D (0.68) HTR1DHTR1BHTR2AMEN1MAPT
Oxalic Acid SCHEMBL6924129 0.76 HTR1D (0.86) HTR1DHTR1BHTR2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1001766-B1 COMPOUNDS FOR THE TREATMENT OF CCR5-MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 2003-04-09 EP claimed
EP-1001766-A4 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORP (US) 2001-04-04 EP disclosed
EP-1001766-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 2000-05-24 EP disclosed
WO-1999001127-A1 COMPOUNDS AND METHODS SMITHKLINE BEECHAM CORPORATION (US) 1999-01-14 WO disclosed